EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiohalogenated Tetrazines for Click Chemistry-Mediated Pretargeted Radioimmunotherapy

Mike A Cornejo, Gina Dehlavi, Zachary V Samuels iD, Wei-Siang Mark Kao, Lukas M Carter, Emilia Strugala, Yutian Feng, Michael R Zalutsky, Brian M Zeglis iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5538-5548

DOI: 10.1021/acs.molpharmaceut.6c00618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 26.09.2026. Verfasst von Mike A Cornejo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hunter College, The City University of New York, New York, New York10021, United States. Hauptthemen laut MEDLINE: Radioimmunotherapy, Radiopharmaceuticals, Click Chemistry. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Division of Graduate Education, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vivo pretargeting is an emergent approach to nuclear imaging and radiopharmaceutical therapy that leverages the exquisite selectivity and affinity of full-length immunoglobulins while skirting their pharmacokinetic and dosimetric limitations. One particularly promising approach to pretargeting is predicated on the inverse electron-demand Diels−Alder reaction between a trans-cyclooctene (TCO)-bearing antibody and a tetrazine (Tz)-based radioligand. This methodology has been validated with a wide variety of antibody-antigen systems paired with radionuclides for positron emission tomography (PET), single photon emission computed tomography (SPECT), and radioimmunotherapy. The halogen group of the periodic table offers an abundance of isotopes that emit β−-particles (i.e. 131I), α-particles (i.e. 211At), and Auger electrons (i.e. 125I) for radiopharmaceutical therapy. Herein, we describe the synthesis and characterization of a pair of Tz radioligands containing 131I-labeled residualizing guanidinium prosthetic groups: iso-[131I]GMIB-PEG6-Tz and iso-[131I]GMIB-Tz. Subsequently, these two radioligands were used in conjunction with a TCO-bearing variant of the A33 antigen-targeting mAb huA33 (i.e. huA33-TCO) for in vivo pretargeting experiments in a murine model of colorectal carcinoma. The biodistribution and dosimetry data from these preclinical experiments suggested that the PEG6-containing radioligand offered a superior pharmacokinetic profile, and protocols were developed for the synthesis of iso-[211At]AGMB-PEG6-Tz. Finally, the in vivo behavior of iso-[211At]AGMB-PEG6-Tz was probed in both healthy mice and in a pretargeting system paired with huA33-TCO in a murine model of colorectal carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadioimmunotherapyRadiopharmaceuticalsClick ChemistryAnimalsMiceHumansTissue DistributionIodine RadioisotopesCyclooctanesTomography, Emission-Computed, Single-PhotonCell Line, TumorMice, NudeFemalePositron-Emission TomographyAntibodies, MonoclonalAstatine

Substanzen

RadiopharmaceuticalsIodine RadioisotopesCyclooctanesAstatine-211Antibodies, MonoclonalAstatine

Autor:innen und Institutionen

  • Department of Chemistry, Hunter College, The City University of New York, New York, New York10021, United States.
  • Ph.D. Program in Chemistry, Graduate Center of the City University of New York, New York, New York10016, United States.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York10065, United States.
  • Ph.D. Program in Biochemistry, Graduate Center of the City University of New York, New York, New York10016, United States.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York10065, United States.
  • Department of Radiology, Duke University Medical Center, Durham, North Carolina27710, United States.

ORCID-Profile: Zachary V Samuels, Brian M Zeglis

Förderung

  • NCI NIH HHS
  • Division of Graduate Education
  • National Institute of Allergy and Infectious Diseases
  • National Cancer Institute

Zitieren

APA

Cornejo, M. A., Dehlavi, G., Samuels, Z. V., Mark Kao, W. S., Carter, L. M., Strugala, E., Feng, Y., Zalutsky, M. R., & Zeglis, B. M. (2026). Radiohalogenated Tetrazines for Click Chemistry-Mediated Pretargeted Radioimmunotherapy. Molecular Pharmaceutics, 23(11), 5538-5548. https://doi.org/10.1021/acs.molpharmaceut.6c00618

Vancouver

Cornejo MA, Dehlavi G, Samuels ZV, Mark Kao WS, Carter LM, Strugala E, et al. Radiohalogenated Tetrazines for Click Chemistry-Mediated Pretargeted Radioimmunotherapy. Molecular Pharmaceutics. 2026;23(11):5538-5548. doi:10.1021/acs.molpharmaceut.6c00618

BibTeX
@article{Cornejo2026,
  author = {Cornejo, Mike A and Dehlavi, Gina and Samuels, Zachary V and Mark Kao, Wei-Siang and Carter, Lukas M and Strugala, Emilia and Feng, Yutian and Zalutsky, Michael R and Zeglis, Brian M},
  title = {Radiohalogenated Tetrazines for Click Chemistry-Mediated Pretargeted Radioimmunotherapy},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5538--5548},
  doi = {10.1021/acs.molpharmaceut.6c00618}
}
Kostenlos starten →